Hematology-American Society of Hematology Education Program

Article	Citations
Your chemo is no good here: management of high-risk MCL	92
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	87
Mastocytosis demystified	63
Recognizing, defining, and managing CAR-T hematologic toxicities	60
Anticoagulation at the end of life: whether, when, and how to treat	50
Labor and delivery: DIC, HELLP, preeclampsia	42
Inpatient recognition and management of HLH	38
On the horizon: upcoming new agents for the management of ITP	37
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	30
The varieties of therapeutic experience: navigating treatment options for patients with PNH	29
Challenges and opportunities in the long-term management of immune-mediated TTP	29
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment	29
Neurological manifestations of MGUS	28
Bispecific antibody therapies	27
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	26
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	25
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	24
New therapies in hemophilia: extend the half-life, mimic, or rebalance?	24
Where do immunotherapies stand in management of acute leukemia in adults?	24
Has PD-1 blockade changed the standard of care for cHL?	23
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	23
Divergent paths: management of early relapsed follicular lymphoma	22
New approaches to tackle cytopenic myelofibrosis	22
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL	22

Donor selection, graft engineering, and dosing oh my!	22
Selecting initial therapy in CLL	22
Troubleshooting heparin resistance	21
How to assess hemostasis in patients with severe liver disease	21
Fitness and frailty in myeloma	21
Optimizing outcomes in secondary AML	21
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	20
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	20
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	19
MGCS: where do we stand today?	19
BV and beyond: how to incorporate novel agents into PTCL management	19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	19
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	19
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	19
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?	18
Management of TKI-resistant chronic phase CML	18
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?	18
Hematology 2022—what is complete HLA match in 2022?	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
How to manage hemostasis in patients with liver disease during interventions	17
Consumptive coagulopathy in the ICU	17
How to diagnose and manage antiphospholipid syndrome	17
What's new in hereditary hemorrhagic telangiectasia?	17
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 202	17
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	17
Demystifying autoimmune HIT: what it is, when to test, and how to treat	17
Management of marginal zone lymphomas	16
Atypical CML: diagnosis and treatment	16
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL	16
Management of limited-stage Hodgkin lymphoma	16
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma	15
Organ function indications and potential improvements following curative therapy for sickle cell disease	15
Special considerations in GI bleeding in VWD patients	15
Thrombosis questions from the inpatient wards	15
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	15
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	14
Approaches to management of HIT in complex scenarios, including cardiac surgery	14
CNS prophylaxis in aggressive B-cell lymphoma	14
Management of autoimmune hemolytic anemia	14
Pregnancy management for patients with bleeding disorders	14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Transplant in AML with measurable residual disease: proceed or defer?	14
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	13
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes	13
Treatment of VTE in the thrombocytopenic cancer patient	13
Alloimmunization and hyperhemolysis in sickle cell disease	13
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma	13

POEMS syndrome: diagnosis, treatments, and outcomes	13
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing	13
Cytoreduction for ET and PV: who, what, when, and how?	13
Pegylated interferon: the who, why, and how	12
Thrombocytopenia in pregnancy	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
What makes a pediatric or young adult patient an appropriate transplant candidate?	12
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS	12
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	12
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	12
Clinical manifestations of telomere biology disorders in adults	12
Ph− ALL: immunotherapy in upfront treatment	12
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS	11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	11
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	11
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era	11
Monoclonal gammopathy of renal significance from a hematologic perspective	11
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	11
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?	11
Future directions in transplantation for aplastic anemia	11
Next-generation therapy for lower-risk MDS	11
Sequencing bispecific antibodies and CAR T cells for FL	10
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD	10
Managing patients with a history of arterial disease and new venous thromboembolism	10
Should we use bisphosphonates to treat bone complications in sickle cell disease?	10
Approach to the patient with suspected hypereosinophilic syndrome	10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	10
Novel therapies upon failure of HMA plus venetoclax	10
Managing side effects: guidance for use of immunotherapies in multiple myeloma	10
The aging hemophilia patient	10
The role of stem cell transplant (auto and allo) in PTCL and CTCL	10
What to know about rare B-cell malignancies in 2025	10
IV iron formulations and use in adults	9
Warm autoimmune hemolytic anemia and the best treatment strategies	9
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	9
When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders	9
Updates in antithrombotic therapy in coronary and peripheral artery disease	9
In 2022, which is preferred: haploidentical or cord transplant?	9
Porphyria cutanea tarda: a unique iron-related disorder	9
The approach of HMA plus VEN with or without BMT for all patients with AML	9
von Willebrand disease and heavy menstrual bleeding: when and how to test	9
Sequencing therapy in relapsed DLBCL	9
Barriers to accessing cellular therapy for patients receiving care in community practices	9
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	9
Molecular surprises in evaluations of red cell disorders	9
Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease	9
What is the best induction for myeloma for the fit patient?	9
When should we use it? The role of brentuximab vedotin in 2024	8
Implementation failure: thromboprophylaxis in ambulatory patients with cancer	8
Management of Fanconi anemia beyond childhood	8
Diagnosis of bleeding disorder of unknown cause: how many tests are enough to diagnose BDUC?	8
Long-term prophylaxis: what are our options and how to define success?	8
Clonal hematopoiesis in frequent whole blood donors	8
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?	8
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	8
Updates in the management of newly diagnosed chronic lymphocytic leukemia	8
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	8
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	8
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	8
New definitions for antiphospholipid syndrome: ready for clinical use?	8
From treatment to biology and back: managing iron overload in transfused hemoglobinopathies	8
Are transplant indications changing for myelofibrosis?	8
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	8
Risk-stratification in frontline CLL therapy: standard of care	7
(Un) Diagnosing von Willebrand disease	7
Using disease-modifying therapies in sickle cell disease	7
Multiple myeloma: a paradigm for blending community and academic care	7
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	7
Novel platelet products including cold-stored platelets	7
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	7
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	7
Diagnosis and management of cold agglutinin disease	7
Amyloid consults do not have to be vexing	7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	7
The first relapse in multiple myeloma: how to pick the next best thing	7
Clonal evolution in inherited marrow failure syndromes predicts disease progression	6
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	6
Maintenance strategies for relapse prevention and treatment	6
Acute lymphoblastic leukemia in young adults: which up-front treatment?	6

Ph+ ALL in 2022: is there an optimal approach?	6
Transplantation in CML in the TKI era: who, when, and how?	6
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?	6
When to consider inherited marrow failure syndromes in adults	6
New investigational combinations for higher-risk MDS	6
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program . 2023;2023(1):573-580.	6
Novel clinical care models for patients with sickle cell disease	6
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	6
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	6
New age HCT conditioning regimens: what works and why?	6
Newborn screening initiatives for sickle cell disease in Africa	6
The intersection of sickle cell disease, stigma, and pain in Africa	6
Renal manifestations of MGUS	6
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	6
Potential and emerging therapeutics for HHT	6
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	6
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	6
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	6
Epidemiology and treatment of priapism in sickle cell disease	5
Current use of bispecific antibodies to treat multiple myeloma	5
Dual-targeted regimens for the frontline treatment of CLL	5
Ph+ ALL: new approaches for upfront therapy	5
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	5
Sickle cell disease in India: the journey and hope for the future	5
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program . 2021;2021:621-627.	5
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	5
How to manage ITP with life-threatening bleeding	5
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program . 2023;2023(1	5
Challenges to successful outcomes in AYAs with ALL and potential solutions	5
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	5
Cellular therapy for multiple myeloma: what's now and what's next	5
Late complications and long-term care of adult CAR T-cell patients	5
Optimizing the “right” patient selection for treatment for sickle cell disease	4
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	4
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	4
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	4
Mutational screening to improve the transplantation decision-making process in MDS	4
Approaches to optimize outcomes in transplant recipients	4
Givosiran: a targeted treatment for acute intermittent porphyria	4
Novel approaches to acute graft-versus-host disease prevention	4
Endless possibilities and how to exploit them? What is the optimal treatment sequence?	4
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	4
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	4
Identifying and treating iron deficiency anemia in pregnancy	4
Current use of CAR T cells to treat multiple myeloma	4
Molecular diagnostics 101: how to use genetic tests in classical hematology	4
Anticoagulants in hematologic malignancies: what is the data?	4
High-grade B-cell lymphomas: high difficulties to diagnose and treat?	4
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	4
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	4
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	4
Optimal approach to T-cell ALL	4
Platelet components and bacterial contamination: hospital perspective 2022	4
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	4
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	4
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	4
Buckle up! Managing surgery in patients with bleeding disorder of unknown cause	4
Deconstructing gene therapy in hemophilia for the clinician	4
The role of MRD monitoring and options for CLL management in relapsed/refractory disease	4